"there’s also less of a chance that this offer by Merck was for a limited time - this deal could’ve been struck well after the trial readout that’s pending"
Keytruda patents expire in 2028, so Merck needed to get this 750 patient trial happening now in order to get FDA approval for the combo before the patent runs out. trial to run 2025-26 and then 2027 for FDA approval and manufacturing ramp up. USA may block the use of Chinese labs.
- Forums
- ASX - By Stock
- IMM
- Immutep
Immutep, page-10
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
(20min delay)
|
|||||
Last
29.0¢ |
Change
-0.010(3.33%) |
Mkt cap ! $421.2M |
Open | High | Low | Value | Volume |
30.0¢ | 30.0¢ | 28.5¢ | $751.3K | 2.589M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
21 | 307462 | 28.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
29.5¢ | 118494 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
20 | 257462 | 0.285 |
18 | 712543 | 0.280 |
6 | 125918 | 0.275 |
11 | 273188 | 0.270 |
7 | 124774 | 0.265 |
Price($) | Vol. | No. |
---|---|---|
0.295 | 118494 | 4 |
0.300 | 623600 | 3 |
0.305 | 191186 | 8 |
0.310 | 507281 | 6 |
0.315 | 138917 | 6 |
Last trade - 16.10pm 10/07/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
SPONSORED BY The Market Online